TY - JOUR
KW - Analgesics, Opioid/therapeutic use
KW - Buprenorphine/therapeutic use
KW - COVID-19
KW - COVID-19 Testing
KW - Humans
KW - Opiate Substitution Treatment
KW - Opioid-Related Disorders/drug therapy
KW - Pandemics
KW - SARS-CoV-2
KW - Telemedicine
KW - Addiction
KW - buprenorphine
KW - Medication for opioid use disorder (MOUD)
KW - Opioid use disorder (OUD)
KW - telehealth
KW - treatment
AU - R. H. Cales
AU - S. C. Cales
AU - J. Shreffler
AU - M. R. Huecker
A1 - 
AD - NuLease Medical Solutions, LLC, Louisville, KY, United States of America. Electronic address: rick@cales.com.; NuLease Medical Solutions, LLC, Louisville, KY, United States of America. Electronic address: shannonc@nulease.com.; University of Louisville, Department of Emergency Medicine, United States of America. Electronic address: jacob.shreffler@louisville.edu.; University of Louisville, Department of Emergency Medicine, United States of America. Electronic address: martin.huecker@louisville.edu.
BT - Journal of substance abuse treatment
C5 - Education & Workforce; Healthcare Disparities; HIT & Telehealth; Opioids & Substance Use
DO - 10.1016/j.jsat.2021.108543
JF - Journal of substance abuse treatment
LA - eng
M1 - Journal Article
PB - Elsevier Inc
PY - 2022
SN - 1873-6483; 0740-5472; 0740-5472
SP - 108543
T1 - The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth
T2 - Journal of substance abuse treatment
TI - The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth
U1 - Education & Workforce; Healthcare Disparities; HIT & Telehealth; Opioids & Substance Use
U2 - 34210567
U3 - 10.1016/j.jsat.2021.108543
VL - 133
VO - 1873-6483; 0740-5472; 0740-5472
Y1 - 2022
Y2 - Feb
ER -